[96a5a0]: / output / allTrials / identified / NCT01999673_identified.json

Download this file

431 lines (431 with data), 18.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
{
"info": {
"nct_id": "NCT01999673",
"official_title": "SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer",
"inclusion_criteria": "* Male or female at least 18 years of age\n* Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)\n* Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic, renal and hepatic function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC\n* Known history of bleeding disorders, eg, von Willebrand disease or hemophilia\n* Cavitary tumors or tumors invading or abutting large blood vessels\n* Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening\n* Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening\n* Grade 2 or higher peripheral neuropathy",
"miscellaneous_criteria": "Key"
},
"inclusion_lines": [
{
"line": "* Male or female at least 18 years of age",
"criterions": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "at least 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "documented stage IIIb/IV non-squamous NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"IIIb",
"IV"
]
}
]
},
{
"exact_snippets": "non-squamous NSCLC",
"criterion": "NSCLC type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "non-squamous"
}
]
},
{
"exact_snippets": "according to the American Joint Committee on Cancer Staging Manual (7th Edition)",
"criterion": "staging manual edition",
"requirements": [
{
"requirement_type": "edition",
"expected_value": "7th"
}
]
}
]
},
{
"line": "* Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required.",
"criterions": [
{
"exact_snippets": "Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy.",
"criterion": "radiographic disease recurrence or progression",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "during or after front-line platinum-based doublet chemotherapy"
}
]
},
{
"exact_snippets": "patients with known epidermal growth factor receptor (EGFR) activating mutations",
"criterion": "epidermal growth factor receptor (EGFR) activating mutations",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "patients with ... anaplastic lymphoma kinase (ALK) translocations",
"criterion": "anaplastic lymphoma kinase (ALK) translocations",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "appropriate targeted treatment should have been used",
"criterion": "appropriate targeted treatment",
"requirements": [
{
"requirement_type": "usage",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Adequate hematologic, renal and hepatic function",
"criterions": [
{
"exact_snippets": "Adequate hematologic ... function",
"criterion": "hematologic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate ... renal ... function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate ... hepatic function",
"criterion": "hepatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC",
"criterions": [
{
"exact_snippets": "Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC",
"criterion": "NSCLC histology",
"requirements": [
{
"requirement_type": "types",
"expected_value": [
"Squamous",
"small cell",
"carcinoid",
"adenosquamous",
"large-cell neuroendocrine",
"mixed histology containing small-cell",
"mixed histology containing squamous-cell"
]
}
]
}
]
},
{
"line": "* Known history of bleeding disorders, eg, von Willebrand disease or hemophilia",
"criterions": [
{
"exact_snippets": "Known history of bleeding disorders",
"criterion": "bleeding disorders",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "von Willebrand disease",
"criterion": "von Willebrand disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "hemophilia",
"criterion": "hemophilia",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Cavitary tumors or tumors invading or abutting large blood vessels",
"criterions": [
{
"exact_snippets": "Cavitary tumors",
"criterion": "cavitary tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "tumors invading ... large blood vessels",
"criterion": "tumor invasion of large blood vessels",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "tumors ... abutting large blood vessels",
"criterion": "tumor abutting large blood vessels",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening",
"criterions": [
{
"exact_snippets": "Clinically significant bleeding such as gross hematuria",
"criterion": "gross hematuria",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": "within the 6 months before screening"
}
]
},
{
"exact_snippets": "Clinically significant bleeding such as ... GI bleeding",
"criterion": "GI bleeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": "within the 6 months before screening"
}
]
},
{
"exact_snippets": "Clinically significant bleeding such as ... hemoptysis",
"criterion": "hemoptysis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": "within the 6 months before screening"
}
]
}
]
},
{
"line": "* Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening",
"criterions": [
{
"exact_snippets": "Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening",
"criterion": "thromboembolic events",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 6,
"unit": "months"
}
]
}
}
]
}
]
},
{
"line": "* Grade 2 or higher peripheral neuropathy",
"criterions": [
{
"exact_snippets": "Grade 2 or higher peripheral neuropathy",
"criterion": "peripheral neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "grade"
}
}
]
}
]
}
],
"miscellaneous_lines": [
{
"line": "Key",
"criterions": [
{
"exact_snippets": "Key",
"criterion": "key",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "N/A"
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}